Medpace Notches A Big Bookings Beat, And Reverses Its First-Quarter Malaise

Licensing

Medpace Holdings (MEDP) stock surged by double digits Thursday, helped by a big bookings beat, rebounding from a poor start to the year. The contract research organization, or CRO, put up a book-to-bill ratio of 1.13x, easily above expectations for 0.95x to 1.01x, according to Leerink Partners analyst Michael Cherny. That means Medpace received more new orders than it can…